Diranersen missed its primary endpoint: proving a dose-dependent response on the CDR-SB, a key measure of cognitive decline. Instead, the trial revealed a baffling "ceiling effect." The lowest dose delivered significant clinical benefits, while higher doses showed steeply diminishing returns.

Diranersen is the first therapy to successfully demonstrate a massive 50% to 65% reduction in cerebrospinal fluid (CSF) total tau alongside significant reductions in brain tau pathology across all doses. By targeting MAPT mRNA, it successfully knocks down both intracellular and extracellular tau.

Unlike anti-amyloid competitors like Leqembi and Kisunla, diranersen showed 0% ARIA (brain swelling or bleeding). Because real-world ARIA rates for existing treatments hover around 10%, diranersen’s clean profile widens its therapeutic window significantly.

While the winning 60 mg dose was well-tolerated (serious adverse events were balanced with placebo at 13%), the higher doses were problematic. The 115 mg arms saw massive discontinuation rates of 20% to 25%, driven by severe procedure-related pain and confusional states.

Analysts remain divided on whether the lowest dose’s 26% slowing of cognitive decline is a win or a miss compared to the 27% to 29% benchmark already set by existing anti-amyloid therapies.

• 
  

  Morgan Stanley (Terence Flynn): Noted the 60mg efficacy landed at the lower end of expectations. He highlighted that management’s inability to provide a credible explanation for the inverse dose response is the primary driver of the stock’s weakness.

  
  


• 
  

  William Blair (Myles Minter): Acknowledged the lower-end efficacy but argued the data proves diranersen is vastly superior to monoclonal antibody approaches. He believes this validates the thesis that knocking down tau inside the cell is the correct path forward.

  
  


• 
  

  Jefferies (Andrew Tsai): Took a more optimistic stance, pointing out that the 60mg dose’s 26% slowing is perfectly in-line with the 23% to 27% slowing seen in Leqembi and Kisunla trials. He theorized that there may simply be an optimal "ceiling" for tau reduction.

  
  

Despite missing the primary endpoint and the market’s negative reaction, the robust biomarker data and the safety profile of the low dose give Biogen exactly what it needs to advance diranersen to Phase 3. However, management faces intense pressure to crack the dosing mystery and refine their patient criteria before locking in the final trial design.